Samsung Bioepis is set to expand its biosimilars business into the Chinese market through a licensing deal that the firm has just struck with China’s 3SBio. Noting that the deal covered “multiple biosimilar candidates”, Samsung Bioepis said this included its SB8 proposed rival to Avastin (bevacizumab).
Samsung Bioepis Eyes China With 3SBio Deal
Samsung Bioepis has struck a licensing agreement with China’s 3SBio that will allow the firm to expand its biosimilars business into the Chinese market. Bevacizumab is among several biosimilar candidates covered by the deal.
